HealthCare Global Enterprises Limited announced that its Nomination and Remuneration Committee has approved the grant of 70,000 Employee Stock Options (ESOS). These options are granted under the HealthCare Global Enterprises Limited-Employee Stock Option Scheme, 2026 (“HCG ESOS 2026”) to eligible employees. The grant aims to incentivize and retain key personnel within the company and its subsidiaries.
HealthCare Global Enterprises Approves ESOS Grant
On November 05, 2026, HealthCare Global Enterprises Limited announced a significant development regarding its employee incentive program. The Nomination and Remuneration Committee of the Board of Directors has officially approved the grant of Employee Stock Options (ESOS) to eligible employees of the company and its subsidiary and associate companies, both within India and internationally.
Details of the ESOS Grant
The approved grant consists of 70,000 Employee Stock Options, which will be issued under the HealthCare Global Enterprises Limited-Employee Stock Option Scheme, 2026 (referred to as “HCG ESOS 2026”). This move is intended to align the interests of employees with those of the shareholders and to foster a performance-driven culture within the organization.
Key Terms of the Scheme
The HCG ESOS 2026 includes several key provisions as outlined in Annexure-A:
- Number of Options Granted: 70,000 options.
- Scheme Compliance: The scheme is in compliance with SEBI (SBEB) Regulations, 2021.
- Share Conversion: Each option, upon exercise, converts into one equity share of the Company with a face value of INR 10/-.
- Exercise Price: The exercise price for these options is set at INR 495 per share.
- Vesting Period: Options will have a vesting period of not less than 1 year and not exceeding 7 years from the grant date.
- Exercise Period: Options can be exercised for a maximum period of 10 years from the grant date, commencing after 6 years from the grant date or upon a change in control event, whichever is earlier. Special provisions are in place for exercising options post a change in control event.
The company has made this information available on its website at https://www.hcgoncology.com/.
Source: BSE
